Clinical Trial Search

Primary: Area Under the Concentration-time Curve of Iclepertin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5014.15; 4702.56; 5099.51…

Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) — 4063.86; 1957.60 hours * nanomole/liter…

Primary: Decrease in Depressive Symptoms — 12.13 Score on MADRS — p=0.0065

Primary: Annualized Rate of Severe Asthma Exacerbation Events Over 48 Weeks — 0.598; 0.463; 0.312; 0.450 exacerbation/participant-year — p=0.3626

Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 7904.16; 6400.59; 7648.23 nanomol (nmol) * hour (h)…

Primary: Change in Resting State Functional Connectivity of the Subgenual Anterior Cingulate Cortex (sgACC) and the Default Mode Network (DMN). — 0.0382; 0.0241; 0.0300; 0.0196…

Primary: Quantification of Antibody Titers — 37.4; 24.6; 6.81 Antibody titer

Primary: Incidence of Major Intra-abdominal Complications — 4; 11 Participants

Primary: Area Under the Concentration-time Curve of Iclepertin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5329.59; 4812.01; 4090.68…

Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 14h (AUC0-14) — 421.0; 829; 1840.0; 3300.0 nanomole*hours/Liter (nmol∙h/L)

Primary: Percent Weight Change Through 16 Sessions — -2.4; -1.3; -1.5; -1.6 percent weight change

Primary: Area Under the Plasma Concentration-time Curve From 0 to 168 Hours Time Point of BI 425809 (AUC0-168). — 8221.87; 843.57 nanomole*hour/Litre (nmol*h/L)

Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage

Primary: Relative Change From Baseline in 24-hour Cough Frequency at Day 21 — -64.92; -9.36 coughs per hour — p=<0.0001

Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants